170 related articles for article (PubMed ID: 17596694)
1. Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador).
Grossarth-Maticek R; Ziegler R
Forsch Komplementmed; 2007 Jun; 14(3):140-7. PubMed ID: 17596694
[TBL] [Abstract][Full Text] [Related]
2. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador).
Grossarth-Maticek R; Ziegler R
Forsch Komplementmed; 2006 Oct; 13(5):285-92. PubMed ID: 17057389
[TBL] [Abstract][Full Text] [Related]
3. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador.
Grossarth-Maticek R; Ziegler R
Arzneimittelforschung; 2007; 57(10):665-78. PubMed ID: 18074761
[TBL] [Abstract][Full Text] [Related]
4. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis.
Grossarth-Maticek R; Ziegler R
Eur J Med Res; 2006 Nov; 11(11):485-95. PubMed ID: 17182361
[TBL] [Abstract][Full Text] [Related]
5. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador).
Grossarth-Maticek R; Ziegler R
Eur J Med Res; 2008 Mar; 13(3):107-20. PubMed ID: 18499556
[TBL] [Abstract][Full Text] [Related]
6. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study.
Grossarth-Maticek R; Kiene H; Baumgartner SM; Ziegler R
Altern Ther Health Med; 2001; 7(3):57-66, 68-72, 74-6 passim. PubMed ID: 11347286
[TBL] [Abstract][Full Text] [Related]
7. Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort Studies for Long-term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador).
Ziegler R; Grossarth-Maticek R
Evid Based Complement Alternat Med; 2010 Jun; 7(2):157-66. PubMed ID: 18955332
[TBL] [Abstract][Full Text] [Related]
8. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
[TBL] [Abstract][Full Text] [Related]
10. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review.
Ostermann T; Raak C; Büssing A
BMC Cancer; 2009 Dec; 9():451. PubMed ID: 20021637
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
12. Targeting inflammation in cancer-related-fatigue: a rationale for mistletoe therapy as supportive care in colorectal cancer patients.
Bock PR; Hanisch J; Matthes H; Zänker KS
Inflamm Allergy Drug Targets; 2014; 13(2):105-11. PubMed ID: 24766319
[TBL] [Abstract][Full Text] [Related]
13. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study.
Bar-Sela G; Wollner M; Hammer L; Agbarya A; Dudnik E; Haim N
Eur J Cancer; 2013 Mar; 49(5):1058-64. PubMed ID: 23218588
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review and Meta-Analysis on the Survival of Cancer Patients Treated with a Fermented Viscum album L. Extract (Iscador): An Update of Findings.
Ostermann T; Appelbaum S; Poier D; Boehm K; Raak C; Büssing A
Complement Med Res; 2020; 27(4):260-271. PubMed ID: 31927541
[TBL] [Abstract][Full Text] [Related]
15. Anticarcinogenic and antimetastatic activity of Iscador.
Kuttan G; Menon LG; Antony S; Kuttan R
Anticancer Drugs; 1997 Apr; 8 Suppl 1():S15-6. PubMed ID: 9179361
[TBL] [Abstract][Full Text] [Related]
16. Pleura carcinosis. Cytomorphological findings with the mistletoe preparation iscador and other pharmaceuticals.
Salzer G
Oncology; 1986; 43 Suppl 1():66-70. PubMed ID: 3808576
[TBL] [Abstract][Full Text] [Related]
17. [Iscador--mistletoe extract for cancer treatment. Documentation No. 10].
Schweiz Rundsch Med Prax; 1988 Jan; 77(4):69-74. PubMed ID: 3279479
[No Abstract] [Full Text] [Related]
18. Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro.
Maier G; Fiebig HH
Anticancer Drugs; 2002 Apr; 13(4):373-9. PubMed ID: 11984083
[TBL] [Abstract][Full Text] [Related]
19. Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer.
Matthes H; Friedel WE; Bock PR; Zänker KS
Curr Mol Med; 2010 Jun; 10(4):430-9. PubMed ID: 20455850
[TBL] [Abstract][Full Text] [Related]
20. Patients are talking about ... Iscador (mistletoe).
Decker G
Clin J Oncol Nurs; 2001; 5(4):183-4. PubMed ID: 12690624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
